This ASX healthcare stock is crashing 30% on half year results

Why is this stock crashing deep into the red today? Let's find out.

| More on:
A man slumps crankily over his morning coffee as it pours with rain outside.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Integral Diagnostics Ltd (ASX: IDX) share price is having a day to forget on Wednesday.

In morning trade, the ASX healthcare stock is down 30% to $2.00.

This follows the release of the medical imaging services provider's half year results.

ASX healthcare stock crashing 30% today

  • Revenue of $252.9 million
  • Operating EBITDA of $46.2 million
  • Operating net profit after tax of $8.8 million
  • Statutory loss after tax of $0.4 million
  • Interim dividend of 2.5 cents per share

What happened during the half?

For the first half, Integral Diagnostics reported consolidated revenue of $252.9 million. This reflects a 7.8% increase in standalone revenue to $249.4 million and a $3.5 million contribution from the Capitol Health business.

As a reminder, Integral Diagnostics and Capitol Health merged late last year to create an almost $1 billion diagnostics imaging group.

Operating EBITDA was $46.2 million for the half. This was driven by an 8.2% increase in Integral Diagnostics EBITDA to $46.8 million, partially offset by an EBITDA loss of $0.6 million from Capitol Health.

On the bottom line, a statutory loss of $0.4 million was record, disappointing the market and sending many investors to the exits.

Commenting on the half, the ASX healthcare stock's CEO, Dr Ian Kadish, said:

On a standalone basis we have seen solid revenue growth in 1H FY25, but have also experienced higher than expected clinical staff cost inflation, particularly in two remote regional areas. The continued organic growth of IDXt and recruitment initiatives will help to address these regional clinical cost challenges.

Dr Kadish remains positive on the future despite the tough half. He said:

The fundamentals of the radiology industry are strong, and will be materially strengthened by further deregulation of MRIs and the introduction of a National Lung Cancer Screening Program (NLCSP) in Australia, both effective from 1 July 2025.

The merger with Capitol Health provides us with increased scale that will improve margins and growth in metropolitan areas. The merger synergies of at least $10.0m before tax annually are on track, and going forward the Company is ideally positioned to materially benefit from the merger synergies, MRI deregulation and the NLCSP.

Outlook

No real guidance was given for the second half. But management advised that it remains focused on key operational improvement initiatives, which are expected to improve its operating EBITDA margin over time.

Furthermore, the integration of IDX and Capitol, following the merger on 20 December 2024, is progressing well and is on track to deliver at least $10 million of annual pre-tax net cost synergies. The majority is expected to be realised within the first year post implementation.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Earnings Results

Why is the QBE share price racing ahead of the benchmark on Friday?

Investors are bidding up QBE shares today. But why?

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Earnings Results

Macquarie share price leaps higher on rising full-year profits

Macquarie reported its full year FY 2025 results today. Here's why ASX investors are reacting enthusiastically.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Technology Shares

Guess which ASX 200 tech stock is crashing 14% on results day

This tech stock is having a rough time today. But why?

Read more »

Worried woman calculating domestic bills.
Earnings Results

ANZ share price falls on half-year results

How did the bank perform during the first half? Let's find out.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Bank Shares

NAB share price jumps on solid half year results

Investors have responded positively to the bank's results.

Read more »

Lines of codes and graphs in the background with woman looking at laptop trying to understand the data.
Earnings Results

Westpac share price sinks on half-year results miss

Let's see how the big four bank performed during the first half.

Read more »

Miner looking at a tablet.
Gold

Newmont share price lifts off on first-quarter results

The ASX 200 gold stock is charging higher on Thursday.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »